• 1
    Riley SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 1997; 0: 7613.
  • 2
    Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; i: 1858.
  • 3
    Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 13839.
  • 4
    The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomised, placebo controlled trial. Ann Intern Med 1996; 124: 20421.
  • 5
    Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 3638.
  • 6
    Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid: Asacol) for the prevention of post-operative recurrence in Crohn's disease. Aliment Pharmacol Ther 1994; 8: 3543.
  • 7
    Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 117983.
  • 8
    Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology 1994; 107: 11720.
  • 9
    Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case–control study. Aliment Pharmacol Ther 2000; 14: 14553.
  • 10
    Van Hees PA, Van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulphasalazine. J Clin Gastroenterol 1982; 4: 3336.
  • 11
    Kane SV, Cohen RD, Aitkens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 292933.
    Direct Link:
  • 12
    Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001; 32: 668.
  • 13
    Kane SV, Hanauer SB. Medication adherence is associated with improved outcomes in patients with quiescent ulcerative colitis (UC) [Abstract]. Gastroenterology 2000; 118: 4900.
  • 14
    Haynes RB. Determinants of compliance: the disease and mechanics of treatment. In: HaynesRB, TaylorDT, SackettDL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press, 1979.
  • 15
    Cienchanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function and costs. Arch Intern Med 2000; 160: 327885.
  • 16
    Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984; 100: 25868.
  • 17
    Peck CL, King NJ. Compliance and the doctor–patient relationship. Drugs 1985; 30: 7884.
  • 18
    Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 18814.
  • 19
    Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 5909.
  • 20
    Puller T, Birtwell AJ, Wiles PG, et al. Use of a pharmacological indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 1989; 44: 5405.
  • 21
    Fletcher SW, Pappius EM, Harper SJ. Measurement of medication compliance in a clinical setting: comparison of three methods in patients prescribed digoxin. Arch Intern Med 1979; 139: 6358.
  • 22
    Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 84657.
  • 23
    Stephenson BJ, Rowe BH, Haynes RB, et al. Is this patient taking the treatment as prescribed? J Am Med Assoc 1993; 269: 277981.
  • 24
    Gilbert JR, Evans CE, Haynes RB, et al. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J 1980; 123: 11922.
  • 25
    Pullar T, Peaker S, Martin MFR, et al. The use of a pharmacological indicator to investigate compliance in patients with a poor response to anti-rheumatic therapy. Br J Rheumatol 1988; 27: 3814.
  • 26
    Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998; 43: 2932.
  • 27
    Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; i: 514.
  • 28
    Irvine EJ, Zhou Q, Thompson AK, et al. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. Am J Gastroenterol 1996; 91: 15718.
  • 29
    Thom DH, Ribisl KM, Stewart AL, et al. Further validation and reliability testing of the Trust in Physician Scale. Med Care 1999; 37: 5107.
  • 30
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 36170.
  • 31
    Hussain FN, Ajjan RA, Moustafa M, et al. Simple method for the determination of 5-aminosalicylic and N-acetyl-5-aminosalicylic acid in rectal tissue biopsies. J Chromatogr B 1998; 716: 25766.
  • 32
    Husdan H, Rappoport A. Estimation of creatinine by the Jaffe reaction: a comparison of three methods. Clin Chem 1968; 14: 22238.
  • 33
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 2130.
  • 34
    Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 4936.
  • 35
    Hilbrands LB, Hoitsma AJ, Keone RA. Medication compliance after renal transplantation. Transplantation 1995; 60: 91420.
  • 36
    Eisen SA, Woodward RS, Miller D, et al. The effect of medication compliance on the control of hypertension. J Gen Intern Med 1987; 2: 298305.
  • 37
    Sackett DL, Snow JC. The magnitude of compliance and non-compliance. In: HaynesRB, TaylorDT, SackettDL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press, 1979.
  • 38
    Aminosalicylates. British National Formulary. London: British Medical Association, September 2001: 4749.
  • 39
    Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001; 15: 5362.
  • 40
    Robertson DAF, Ray J, Diamond I, et al. Personality profile and affective state of patients with inflammatory bowel disease. Gut 1989; 30: 6236.
  • 41
    Andrews H, Barczak P, Allan RN. Psychiatric illness in patients with inflammatory bowel disease. Gut 1987; 28: 16004.
  • 42
    Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 1973; 14: 9236.
  • 43
    Bardazzi G, D'Albasio G, Bonanomi AG, et al. Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis. Ital J Gastroenterol 1994; 26: 3347.
  • 44
    Dickinson RJ, King A, Wright DGD, et al. Is continuous sulphasalazine necessary in the management of patients with ulcerative colitis? Results of a preliminary study. Dis Colon Rectum 1985; 28: 92930.
  • 45
    Cramer JA, Scheyer RD, Mattson RH. Compliance declines between visits. Arch Intern Med 1990; 150: 150910.